Atlas Trials

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

Clinical trial NCT04427293 · RECRUITING

Trial details

NCT number
NCT04427293
Sponsor
University of Illinois at Chicago
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2020-07-09
Primary completion
2026-07-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.